Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99


Search Results: 1 - 3 of 3 matches for " Archawin Rojanawiwat "
All listed articles are free for downloading (OA Articles)
Page 1 /3
Display every page Item
Safety of the aqueous extract of Portulaca grandiflora Hook in healthy volunteers
Pranee Chavalittumrong,Busarawan Sriwanthana,Archawin Rojanawiwat,Rungrueng Kijphati
Songklanakarin Journal of Science and Technology , 2007,
Abstract: A phase 1 clinical trial was performed in 16 healthy volunteers to primarily investigate safety of Portulaca grandiflora (P. grandiflora) as well as to preliminarily assess its efficacy on the immune system. The volunteers received 500 mg/day of P. grandiflora aqueous extract (250 mg capsule twice daily) for 2 months. No major side effects were reported from any of the subjects throughout the study. It was found that some significant changes in biochemical parameters were within normal limits. Hematological and immunological parameters were not altered after oral administration of P. grandiflora. Our results indicated that the P. grandiflora aqueous extract at the dose of 500 mg/day given to normal volunteers for 2 months was safe.
HIV infection and risk factors among Bangkok prisoners, Thailand: a prospective cohort study
Hansa Thaisri, John Lerwitworapong, Suthon Vongsheree, Pathom Sawanpanyalert, Chanchai Chadbanchachai, Archawin Rojanawiwat, Wichuda Kongpromsook, Wiroj Paungtubtim, Pongnuwat Sri-ngam, Rachaneekorn Jaisue
BMC Infectious Diseases , 2003, DOI: 10.1186/1471-2334-3-25
Abstract: A prospective cohort of 689 male inmates in a Bangkok central prison was studied during 2001–2002. Follow up visits were conducted for 5 months, with testing for HIV and other infections and interviewing of demographics and risk behaviors.Among 689 male inmates, half (50.9 %) were drug injectors. About 49% of the injectors had injection during incarceration. Most (94.9%) of the injectors had shared injection paraphernalia with others. Successful follow up rate was 98.7% after 2,581 person-months observation. HIV incidence was 4.18 per 100 person – years among all inmates, and 11.10 per 100 person – years among the injection inmates. Multivariate analysis identified variables associated with HIV prevalence: history of injection [OR = 2.30, 95%CI: 1.91–2.77], positive urine opiate test [OR = 5.04, 95%CI: 2.63–9.67], history of attendance to drug withdrawal clinics [OR = 2.00, 95%CI: 1.19–3.35] and presence of tattoos on the body [OR = 1.23, 95%CI: 1.01–1.52].The main HIV risk factors of Bangkok inmates were those related to drug injection. Harm reduction measures and HIV intervention strategies should be implemented to prevent more spread of HIV among the inmates and into the community.The problem of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) is usually approached from a perspective of risk behaviors and modes of transmission. In Thailand, this approach has been implemented since 1989 for HIV sentinel surveillance of certain high-risk people; e.g. commercial sex workers, injection drug users and male clients attending sexually transmitted diseases clinics [1]. As far as interventions are concerned, such an approach leaves certain target groups not presenting at the usual settings unaccounted for. For instance, men who have sex with men do not have "well-defined" physical places where they usually meet and are less likely to receive targeted HIV-1 related interventions. On the other hand, certain HIV high-risk groups in w
Impact of HIV vaccination on laboratory diagnosis: case reports
Vongsheree Suthon, Rojanawiwat Archawin, Chardbanchachai Chanchai, Lerwitworapong John, Kongpromsook Wichuda, Paungtubtim Wiroj, Thaisri Hansa, Sawanpanyalert Pathom, Sri-ngam Pongnuwat, Pithak Silaporn, Inunchot Wimala
BMC Infectious Diseases , 2002, DOI: 10.1186/1471-2334-2-19
Abstract: The participants were identified from a cohort study on "Health factors related to HIV-1 and other viral infections among incarcerated people" that was approved by The Ethical Committee for Research in Human Subjects, Ministry of Public Health, Thailand. HIV diagnosis was definitively established with serial specimens using multi-screening tests, Western blot and diagnostic PCR.Anti-HIV screening tests consistently exhibited either weakly reactive or inconclusive results. The band patterns of the Western blot analysis corresponded to those found in individuals who received the rgp120 vaccination. Definite results were established using diagnostic PCR, which exhibited consistently negative results with follow-up specimens. Such problems in HIV testing are not easily resolved in the routine clinical setting in Thailand.These data demonstrate that HIV-1 vaccination interferes with routine diagnostic tests. Similar cases will not be uncommon in Thailand, where 2,545 people have already participated in a phase III trial.At present, there is only one protective human immunodeficiency virus type 1 (HIV-1) vaccine undergoing phase III trials.[1,2] In 1998, the phase I/II trial was conducted among 33 injecting drug users in Bangkok, Thailand, using rgp 120 derived from HIV 1 subtype B (MN). The preliminary data of the phase I/II trials demonstrated acceptable safety and immunogenicity, with some breakthrough infections. Then, a randomized (ratio1: 1), double-blind, placebo-controlled phase III trial, using a bivalent rgp 120 vaccine derived from subtype B (MN) and subtype E (244), was initiated in March 1999, in Bangkok, Thailand, with 2,545 injecting drug users. The final result on the efficacy of this vaccine may be expected in late 2003. Indeed, almost 100% of vaccinated individual seroconverted following immunization and developed a high antibody titer.[3,4] The development of antibody following vaccination would be predicted to interfere with anti-HIV screening tests bu
Page 1 /3
Display every page Item

Copyright © 2008-2017 Open Access Library. All rights reserved.